oxymetazoline hydrochloride · Rvl Pharms · NDA 212520
Upneeq
Earliest generic entry, as listed
16 Dec 2039
Blocked by patent: US 10799481, US 10814001, US 10898573, US 10940138, US 11103482, US 11311515, US 11324722, US 11541036, US 11701343, US 12605363, US 12648930.
Listed patents · 14 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10799481 | use U-2849 · sets the listed date | 16 Dec 2039 |
| US 10814001 | drug product · sets the listed date | 16 Dec 2039 |
| US 10898573 | drug product · sets the listed date | 16 Dec 2039 |
| US 10940138 | use U-2849 · sets the listed date | 16 Dec 2039 |
| US 11103482 | drug product · sets the listed date | 16 Dec 2039 |
| US 11311515 | drug product · sets the listed date | 16 Dec 2039 |
| US 11324722 | use U-2849 · sets the listed date | 16 Dec 2039 |
| US 11541036 | drug product · sets the listed date | 16 Dec 2039 |
| US 11701343 | use U-2849 · sets the listed date | 16 Dec 2039 |
| US 12605363 | drug product · sets the listed date | 16 Dec 2039 |
| US 12648930 | use U-2849 · sets the listed date | 16 Dec 2039 |
| US 10912765 | use U-2849 | 26 Aug 2031 |
| US 8357714 | use U-2849 | 26 Aug 2031 |
| US 9867808 | use U-2849 | 26 Aug 2031 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 212520 · 001 · RLD | solution/drops, ophthalmic | 0.1% | 16 Dec 2039 |